These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33932591)

  • 1. Negatively charged nanoparticles of multiple materials inhibit shear-induced platelet accumulation.
    Griffin MT; Ashworth K; Hill N; von Behren J; Di Paola J; Ku DN
    Nanomedicine; 2021 Jul; 35():102405. PubMed ID: 33932591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of high shear arterial thrombosis by charged nanoparticles.
    Griffin MT; Zhu Y; Liu Z; Aidun CK; Ku DN
    Biomicrofluidics; 2018 Jul; 12(4):042210. PubMed ID: 29887934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor.
    Kageyama S; Yamamoto H; Nagano M; Arisaka H; Kayahara T; Yoshimoto R
    Br J Pharmacol; 1997 Sep; 122(1):165-71. PubMed ID: 9298543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets.
    Alevriadou BR; Moake JL; Turner NA; Ruggeri ZM; Folie BJ; Phillips MD; Schreiber AB; Hrinda ME; McIntire LV
    Blood; 1993 Mar; 81(5):1263-76. PubMed ID: 8443388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target.
    Gragnano F; Golia E; Natale F; Bianchi R; Pariggiano I; Crisci M; Diana V; Fimiani F; Limongelli G; Russo M; Cirillo P; Calabrò P
    Curr Vasc Pharmacol; 2017; 15(5):404-415. PubMed ID: 28155617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels.
    Nimjee SM; Dornbos D; Pitoc GA; Wheeler DG; Layzer JM; Venetos N; Huttinger A; Talentino SE; Musgrave NJ; Moody H; Rempel RE; Jones C; Carlisle K; Wilson J; Bratton C; Joseph ME; Khan S; Hoffman MR; Sommerville L; Becker RC; Zweier JL; Sullenger BA
    Mol Ther; 2019 Jul; 27(7):1228-1241. PubMed ID: 30987839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels.
    Lehmann M; Ashworth K; Manco-Johnson M; Di Paola J; Neeves KB; Ng CJ
    J Thromb Haemost; 2018 Jan; 16(1):104-115. PubMed ID: 29064615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting shear gradient activated von Willebrand factor by the novel single-chain antibody A1 reduces occlusive thrombus formation in vitro.
    Hoefer T; Rana A; Niego B; Jagdale S; Albers HJ; Gardiner EE; Andrews RK; Van der Meer AD; Hagemeyer CE; Westein E
    Haematologica; 2021 Nov; 106(11):2874-2884. PubMed ID: 33054112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chimeric monoclonal antibody MHCSZ-123 against human von Willebrand factor A3 domain inhibits high-shear arterial thrombosis in a Rhesus monkey model.
    Ji S; Jiang M; Yan B; Shen F; He Y; Wan A; Xia L; Ruan C; Zhao Y
    J Hematol Oncol; 2017 May; 10(1):111. PubMed ID: 28526067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent Thrombolytic Effect of
    Martinez de Lizarrondo S; Gakuba C; Herbig BA; Repessé Y; Ali C; Denis CV; Lenting PJ; Touzé E; Diamond SL; Vivien D; Gauberti M
    Circulation; 2017 Aug; 136(7):646-660. PubMed ID: 28487393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis.
    Petzold T; Thienel M; Konrad I; Schubert I; Regenauer R; Hoppe B; Lorenz M; Eckart A; Chandraratne S; Lennerz C; Kolb C; Braun D; Jamasbi J; Brandl R; Braun S; Siess W; Schulz C; Massberg S
    Sci Transl Med; 2016 Nov; 8(367):367ra168. PubMed ID: 27903864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atherosclerotic geometries exacerbate pathological thrombus formation poststenosis in a von Willebrand factor-dependent manner.
    Westein E; van der Meer AD; Kuijpers MJ; Frimat JP; van den Berg A; Heemskerk JW
    Proc Natl Acad Sci U S A; 2013 Jan; 110(4):1357-62. PubMed ID: 23288905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-human VWF monoclonal antibody SZ-123 prevents arterial thrombus formation by inhibiting VWF-collagen and VWF-platelet interactions in Rhesus monkeys.
    Zhao YM; Jiang M; Ji SD; He Y; Shen F; Li XM; Ruan CG
    Biochem Pharmacol; 2013 Apr; 85(7):945-53. PubMed ID: 23295157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys.
    Kageyama S; Yamamoto H; Nakazawa H; Matsushita J; Kouyama T; Gonsho A; Ikeda Y; Yoshimoto R
    Arterioscler Thromb Vasc Biol; 2002 Jan; 22(1):187-92. PubMed ID: 11788481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human neutrophil peptide-1 inhibits thrombus formation under arterial flow via its terminal free cysteine thiols.
    McDaniel JK; Abdelgawwad MS; Hargett A; Renfrow MB; Bdeir K; Cao W; Cines DB; Zheng XL
    J Thromb Haemost; 2019 Apr; 17(4):596-606. PubMed ID: 30741476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs.
    De Meyer SF; Vanhoorelbeke K; Ulrichts H; Staelens S; Feys HB; Salles I; Fontayne A; Deckmyn H
    Cardiovasc Hematol Disord Drug Targets; 2006 Sep; 6(3):191-207. PubMed ID: 17017902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-selectin can promote thrombus propagation independently of both von Willebrand factor and thrombospondin-1 in mice.
    Prakash P; Nayak MK; Chauhan AK
    J Thromb Haemost; 2017 Feb; 15(2):388-394. PubMed ID: 27943541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnesium maintains endothelial integrity, up-regulates proteolysis of ultra-large von Willebrand factor, and reduces platelet aggregation under flow conditions.
    Dong JF; Cruz MA; Aboulfatova K; Martin C; Choi H; Bergeron AL; Martini SR; Kroll MH; Kent TA
    Thromb Haemost; 2008 Mar; 99(3):586-93. PubMed ID: 18327408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner.
    Bao J; Xiao J; Mao Y; Zheng XL
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):397-407. PubMed ID: 24357063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant botrocetin-2 inhibits von Willebrand factor-induced platelet agglutination.
    Matsui T; Hori A; Hamako J; Matsushita F; Ozeki Y; Sakurai Y; Hayakawa M; Matsumoto M; Fujimura Y
    J Thromb Haemost; 2017 Mar; 15(3):538-548. PubMed ID: 28071872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.